GENERAL ORGANIZATION AND BUSINESS (Details Narrative)		3 Months Ended		4 Months Ended	12 Months Ended
	Feb. 12, 2018 Number shares	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)	Apr. 30, 2019 USD ($) Number	Nov. 10, 2011 USD ($)	Dec. 31, 2018 USD ($)
Common stock issued to shareholders			$ 1,250,000
Accumulated deficit		(24,364,149)				$ (23,412,269)
Net cash used in operating activities		(54,348)	(210,553)
Cash in hand		8,000
Proceeds from issuance of notes payable to related parties		50,000
10% Notes Payable [Member]
Proceeds from issuance of notes payable to related parties		$ 50,000		$ 339,144
Number of related party | Number				2
Contribution Agreement [Member] | CureDM Group Holdings, LLC [Member]
Number of shares issued | shares	47,741,140
Number of shares issued at time of delivered | shares	25,000,000
Number of shares issued at time of milestone | shares	22,741,140
Number of shares issued per tranche | shares	5,685,285
Number of tranches for delivered | Number	4
Agreement and Plan of Merger Member [Member] | Boston Therapeutics, Inc. [Member]
Common stock issued to shareholders					$ 4,000,000
Percentage of outstanding common stock					100.00%